Brett Howell, Divisional President, presents an overview of DILIsym® software, Acetaminophen risk assessment, and observations in his presentation titled, “Application of the DILIsym® QST drug-induced liver injury software to evaluate the carcinogenic hazard potential of acetaminophen.”
- Applications of DILIsym along the drug development pipeline
- DILIsym validation submitted: Fit for Purpose focus
- Examination of dose-response of APAP
- and more!
Presented at SLP MIDD+ Virtual Conference March 3-4, 2021